College of Pharmacy and School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, 453003, China.
Department of Drug and Cosmetics Supervision, Henan Food and Drug Administration, Zhengzhou, 450018, China.
Sci Rep. 2017 Mar 2;7:43508. doi: 10.1038/srep43508.
Endothelial dysfunction, which is caused by endothelial nitric oxide synthase (eNOS) uncoupling, is an initial step in atherosclerosis. This study was designed to explore whether Chinese medicine xin-mai-jia (XMJ) recouples eNOS to exert anti-atherosclerotic effects. Pretreatment of XMJ (25, 50, 100 μg/ml) for 30 minutes concentration-dependently activated eNOS, improved cell viabilities, increased NO generations, and reduced ROS productions in human umbilical vein endothelial cells incubated with HO for 2 hours, accompanied with restoration of BH4. Importantly, these protective effects produced by XMJ were abolished by eNOS inhibitor L-NAME or specific eNOS siRNA in HO-treated cells. In ex vivo experiments, exposure of isolated aortic rings from rats to HO for 6 hours dramatically impaired acetylcholine-induced vasorelaxation, reduced NO levels and increased ROS productions, which were ablated by XMJ in concentration-dependent manner. In vivo analysis indicated that administration of XMJ (0.6, 2.0, 6.0 g/kg/d) for 12 weeks remarkably recoupled eNOS and reduced the size of carotid atherosclerotic plaque in rats feeding with high fat diet plus balloon injury. In conclusion, XMJ recouples eNOS to prevent the growth of atherosclerosis in rats. Clinically, XMJ is potentially considered as a medicine to treat patients with atherosclerosis.
内皮功能障碍是动脉粥样硬化的初始步骤,其是由内皮型一氧化氮合酶(eNOS)解偶联引起的。本研究旨在探讨中药心麦甲(XMJ)是否通过重新偶联 eNOS 发挥抗动脉粥样硬化作用。XMJ(25、50、100μg/ml)预处理 30 分钟可浓度依赖性地激活 eNOS,提高细胞活力,增加 NO 的产生,并减少 HO 孵育 2 小时后人脐静脉内皮细胞中的 ROS 产生,同时恢复 BH4。重要的是,HO 处理细胞中 eNOS 抑制剂 L-NAME 或特异性 eNOS siRNA 消除了 XMJ 产生的这些保护作用。在离体实验中,HO 暴露于大鼠离体主动脉环 6 小时可显著损害乙酰胆碱诱导的血管舒张,降低 NO 水平并增加 ROS 产生,而 XMJ 可浓度依赖性地消除这些作用。体内分析表明,XMJ(0.6、2.0、6.0g/kg/d)给药 12 周可显著重新偶联 eNOS,并减少高脂饮食加球囊损伤大鼠颈动脉粥样硬化斑块的大小。总之,XMJ 重新偶联 eNOS 可预防大鼠动脉粥样硬化的生长。临床上,XMJ 可能被认为是治疗动脉粥样硬化患者的药物。